Mesothelioma Prognosis

Mesothelioma Prognosis is the term used by doctors to describe the likely outcome of a disease, how long a diagnosed patient is expected to live, and the quality of life expected during that time. Diffuse malignant mesothelioma is an extremely aggressive disease, and the prognosis is very poor, both for pleural mesothelioma (lung related) and peritoneal mesothelioma (abdominal), as well as pericardial mesothelioma (heart related). Median survival time of 6 to 18 months after diagnosis is reported.

Mesothelioma Prognosis There are a variety of details in the advancement of a person's mesothelioma prognosis and fine differences amongst these details may have a dramatic impact on the course the disease will take. The statistical models employed in mesothelioma often miss the extraordinary differences between a person's stated prognosis/diagnosis and the way in which the disease actually impacts his or her life.

Stage is important for determining mesothelioma prognosis because it can be for other cancers. However, mesothelioma stats are hard to find, and the stats that exist are unreliable. Early diagnosis and remedy are alot of important in looking for a favorable mesothelioma prognosis. Since mesothelioma is usually diagnosed at an advanced stage, the statistics for you to five year survival are usually unreliable. At Stage IV, mesothelioma has spread to other organs, and since a cure is not possible, the mesothelioma prognosis is poor. Remedy at this stage consists mainly of pain management and supportive care.

The latency period with this disease is usually 10 to 30 years, and symptoms include breathing difficulties and a decrease in the elasticity of the lungs. Effusions, both pleural and peritoneal, represent major symptomatic problems for at least two thirds of the patients. Unfortunately, the duration of symptom control is short-lived. Single agent and combimed chemotherapy have reported higher response rates in STAGE II patients, however the toxicity reported is also higher and there is no evidence which combination treatments cause longer survival or longer control of the symptoms.

Related Posts: